NeuroSearch was developing brasofensine (or NS 2214), an oral dopamine reuptake inhibitor for the treatment of Parkinson's disease. Brasofensine successfully passed phase II clinical trial in patients with Parkinson's disease, The drug was safe and well tolerated. However, NeuroSearch discontinued the development of the drug because of the cis-anti isomerization of the 2α-methyloxime group of brasofensine in favor of NS 2230.

Dexsecoverine ia an antimuscarinic drug.

Fenaperone exerts tranquilizing and neuroleptic properties.

Tolgabide is a gabamimetic agent. It exhibits antiepileptic, anticonvulsant and antidyskinetic activity. Tolgabide has a very similar structure and biological properties to those of progabide.

Tilozepine is a thienobenzazepine derivative patented Wander A.-G. as hypnotic, sedative, antipsychotic, and muscle relaxant. Tilozepine acts as a non-selective antagonist of dopamine receptors and shows neuroleptic activity in animal models.

Sulfasymazine is a sulfanilamide derivative patented by American Cyanamid Co. as antibacterial agents for Staphylococcus and Streptococcus infections. In preclinical models, Sulfasymazine shows activity on a dosage basis ranged from 2- to 10-fold that of sulfisoxazole, and from 1/3 to equal on a blood-level basis, but was not as potent as sulfadiazine.

Soraprazan (remofuscin), a potassium-competitive acid blocker (P-CAB; formerly called an acid pump antagonist [APA]), is being developed by Katairo GmbH for the treatment of Stargardt's disease and dry age-related macular degeneration (AMD). Clinical development is underway for Stargardt's disease and dry age-related macular degeneration in the Netherlands and Germany. On 13 November 2013, orphan designation was granted by the European Commission to Katairo GmbH, Germany, for soraprazan for the treatment of Stargardt’s disease. Soraprazan is a a highly potent reversible, and fast-acting inhibitor of gastric H,K-ATPase. Soraprazan shows immediate inhibition of acid secretion in various in vitro models and in vivo and was found to be more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases.

Mezilamine is a dopamine antagonist, it blocks presynaptic but stimulates postsynaptic alpha-adrenoceptors. Potential antipsychotic drug.

Furethidine, a pethidine analog was studied as an analgesic agent. This compound is not currently used in medicine and is listed in schedules of the single convention on narcotic drugs of 1961 as amended by the 1972 protocol.

IQUINDAMINE is an antitussive agent.